Evofem Biosciences Operating Income 2013-2022 | EVFM
Evofem Biosciences operating income from 2013 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Evofem Biosciences Annual Operating Income (Millions of US $) |
2021 |
$-167 |
2020 |
$-104 |
2019 |
$-53 |
2018 |
$-78 |
2017 |
$-36 |
2016 |
$-12 |
2015 |
$-42 |
2014 |
$-10 |
2013 |
$-14 |
2012 |
$-6 |
Evofem Biosciences Quarterly Operating Income (Millions of US $) |
2022-03-31 |
$-29 |
2021-12-31 |
$-37 |
2021-09-30 |
$-43 |
2021-06-30 |
$-41 |
2021-03-31 |
$-45 |
2020-12-31 |
$-36 |
2020-09-30 |
$-26 |
2020-06-30 |
$-22 |
2020-03-31 |
$-19 |
2019-12-31 |
$-13 |
2019-09-30 |
$-14 |
2019-06-30 |
$-12 |
2019-03-31 |
$-14 |
2018-12-31 |
$-15 |
2018-09-30 |
$-18 |
2018-06-30 |
$-23 |
2018-03-31 |
$-21 |
2017-12-31 |
$-15 |
2017-09-30 |
$-9 |
2017-06-30 |
$-6 |
2017-03-31 |
$-5 |
2016-12-31 |
$-2 |
2016-09-30 |
$-2 |
2016-06-30 |
$-3 |
2016-03-31 |
$-6 |
2015-12-31 |
$-9 |
2015-09-30 |
$-17 |
2015-06-30 |
$-9 |
2015-03-31 |
$-7 |
2014-12-31 |
$-3 |
2014-09-30 |
$-2 |
2014-06-30 |
$-2 |
2014-03-31 |
$-2 |
2013-12-31 |
|
2012-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.011B |
$0.008B |
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
|